Signet Therapeutics to Present at the 4th Organoid Congress on AI-Integrated Organoid Models for Oncology Drug Discovery

On August 30-31, 2024, the "2024 (4th) Organoid Conference — Organoids and New Drug Development" will be held in Beijing. As one of the earliest organoid conferences in China, the event has invited leading figures, scholars, and investors from domestic and international universities, research institutions, well-known investment firms, and enterprises related to biomedical engineering to gather and discuss a new blueprint for the development of the organoid industry.

SIGNET, as the first innovative targeted drug research and development company in China based on organoid disease models + AI, was invited to participate in the conference for "Organoid Disease Models Integrated with AI Empower Innovation in Targeted Cancer Drug Development" Special Topic Sharing.

Organoid technology is recognized as one of the most groundbreaking frontier technologies in the biopharmaceutical field in recent years. It can highly simulate the physiological structure and function of human organs, bringing new methods for drug evaluation. Signet Therapeutics' organoid disease model platform effectively bridges the significant gap between animal models and real human responses in traditional drug evaluation methods, improving the efficiency and accuracy of drug testing and accelerating new drug development. The company's first targeted drug, sigx1094, obtained FDA IND approval in just over three years, and this drug will also be the world's first effective targeted therapy for diffuse gastric cancer, which currently has no available treatment.

Meeting Name：2024 (4th) Organoid Conference — Organoids and New Drug Development

Sharing Time: August 31, 11:15-11:45

Organizer: BioValley

Registration Channel：

Signet Therapeutics is the first biotech company in China to develop innovative targeted cancer drugs based on organoid disease models and AI. It was initially founded on the Harvard University campus and established its presence in Shenzhen in 2020, completing an angel round of financing worth nearly 150 million RMB within a year. SIGNET is not only a transliteration of Signet but also adheres to the vision of "Hopeful Ambition, Investigating Things to Gain Knowledge." The company leverages the critical role of organoid disease models that closely resemble patient genomic characteristics in drug efficacy evaluation and new target discovery, integrating AI-powered screening, synthesis, and optimization of small molecule compounds to develop first-in-class innovative targeted therapies. Currently, the company has three drug pipelines, with the lead pipeline developing the world’s first targeted drug for diffuse gastric cancer, which has now entered clinical trials. The company operates a 1,200-square-meter R&D facility and a 500-square-meter animal laboratory. Signet Therapeutics' disease model platform not only supports its own drug pipelines but also actively empowers large pharmaceutical companies in their new drug development efforts, facilitating the creation of more innovative medicines.